Abstracts tagged "cytokines"

Abstract Number: 1087 • ACR Convergence 2020
Plasma-derived Extracellular Vesicles Induced STING-mediated Proinflammatory Effects in Dermatomyositis
Yubin Li¹, Christina Bax², Jay Patel³, Adarsh Ravishankar³, Krisha Desai⁴, Majid Zeidi⁴, Muhammad Bashir⁴ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania, Department of Dermatology, Philadelphia, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Dermatomyositis (DM) is an acquired inflammatory myopathy characterized by chronic skin inflammation. The pathogenesis of DM is still unclear. Extracellular vesicles (EVs) are lipid…
Abstract Number: 1634 • ACR Convergence 2020
Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?
Therese Posas-Mendoza¹, Cara McLeod¹, William Davis² and Robert Quinet², ¹Ochsner Medical Center, New Orleans, LA, ²Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH…
Abstract Number: 0300 • ACR Convergence 2020
Exposure to Topical Antimicrobials Reduces Inflammatory Gene Expression in Cutaneous Lupus Lesional Skin
Sirisha Sirobhushanam¹, Allison Billi², Alex Tsoi², Celine Berthier², Johann Gudjonsson³ and J. Michelle Kahlenberg⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann ArborUniversity of Michigan, ⁴Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Lupus lesional skin has elevated interferon expression, is highly colonized with Staphylococcus aureus (50%) and has no FDA-approved treatment options. S. aureus is known…
Abstract Number: 1209 • ACR Convergence 2020
The Strength of IL-6/STAT3 Signal Inhibition by SAR S.c q2w Showed Significantly Higher Level Than That of TCZ S.c q2w but Lower Than TCZ S.c q1w
Shuntaro Saito¹, Katsuya Suzuki², Keiko Yoshimoto², Yasushi Kondo², Jun Kikuchi², Kotaro Otomo², Hironari Hanaoka², Yuko Kaneko² and Tsutomu Takeuchi³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Interleukin-6 (IL-6) is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab (TCZ) and Sarilumab (SAR) are monoclonal antibodies that bind to…
Abstract Number: 1803 • ACR Convergence 2020
Ability of Innate, Adaptive, and TNF-Superfamily Immune Pathways to Characterize Disease Activity and Inform a Refined Lupus Disease Activity Immune in a Confirmatory Cohort of SLE Patients
Melissa Munroe¹, Wade DeJager², Susan Macwana², Ly Tran², Joel Guthridge², Eldon Jupe³, Daniele DeFreese³, Ryan Newhardt³, Mohan Purushothaman³, Sanjiv Sharma³, Nancy Redinger², Teresa Aberle², Stan Kamp², Cristina Arriens², Eliza Chakravarty², Joan Merrill⁴ and Judith James⁵, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease driven by complex immune dysregulation, involving altered immune mediators and accumulation of autoantibody (AutoAb) specificities.…
Abstract Number: 0458 • ACR Convergence 2020
Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
Bibi Ayesha¹, Anand Kumthekar¹, Ruchi Jain², Sneha Patel³, Manish Ramesh¹, Denisa Ferastraoaru⁴, Golda Hudes⁴, Merhunisa Karagic⁴, Sheema Zafar¹, Rachel Bartash⁴, Natalia Vasquez-Canizares⁵, Elizabeth Kitsis⁶, Clement Tagoe⁷, Dawn Wahezi⁵, Tamar Rubinstein⁸ and Anna Broder³, ¹Montefiore Medical Center, Bronx, NY, ²Montefiore Medical Center, Irvington, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁴Montefiore Medical Center, Bronx, ⁵Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine, New York, NY, ⁷Albert Einstein College of Medicine, Fresh Meadows, NY, ⁸Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY
Background/Purpose: Coronavirus disease (COVID-19) infected patients present with a state of ongoing inflammation and an exaggerated inflammatory state due to unregulated cytokine release called the…
Abstract Number: 1217 • ACR Convergence 2020
Effects of JAK Inhibitors Against JAK2-mediated Signaling in Innate Immune Cells
Yuya Fujita¹, Naoki Matsuoka¹, Makiko Furuya-Yashiro², Jumpei Temmoku², Yuki Kuroiwa³, Masaru Tanaka⁴, Tomoyuki Asano², Shuzo Sato⁵, Haruki Matsumoto², Hiroshi Watanabe², Hideko Kuzuru⁶, Hiroshi Yatsuhashi⁷, Atsushi Kawakami⁸ and Kiyoshi Migita⁹, ¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan, ²Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ³Eli Lilly Japan K.K., Tokyo, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ⁶NHO Nagasaki Medical Center, Clinical Research Center, Omura, Japan, ⁷NHO Nagasaki Medical Center, Clinical Research Center, Omura, Nagasaki, Japan, ⁸Nagasaki University Graduate School of Biomedical Sciences, Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki, Nagasaki, Japan, ⁹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Fukushima, Japan
Background/Purpose: Janus kinase (JAK) family is comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). JAKs form homo- or hetero-complexes, the combination of which…
Abstract Number: 1809 • ACR Convergence 2020
Serum Cytokine Profiling in Systemic Lupus Erythematosus, Analysed Using Unsupervised Machine Learning, Reveals Clinically Relevant Clusters
Fabien Vincent¹, Jannina Ong¹, Alberta Hoi², Sarah Boyd¹, Hieu Nim¹ and Eric Morand³, ¹Monash University, Clayton, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: SLE is a heterogeneous disease, where a better understanding of molecular differences between patients is needed in order to direct therapy. Existing approaches generally…
Abstract Number: 019 • 2020 Pediatric Rheumatology Symposium
Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome
Mingce Zhang ¹, Remy Cron ¹, Devin Absher ², Prescott Atkinson ¹, W. Winn Chatham ¹ and Randy Cron¹, ¹University of Alabama at Birmingham, Birmingham, ²HudsonAlpha Institute for Biotechnology, Huntsville
Background/Purpose: Cytokine storm syndromes (CSS), such as macrophage activation syndrome (MAS) and secondary hemophagocytic lymphohistiocytosis (HLH), are life threatening conditions that commonly present with unremitting…
Abstract Number: 154 • 2020 Pediatric Rheumatology Symposium
T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis
Anna Patrick¹, Tashawna Esmond ², David Flaherty ², Thomas Brent Graham ², Susan Thompson ³ and Thomas Aune ¹, ¹Vanderbilt University Medical Center, Nashville, Tennessee, ²Vanderbilt University Medical Center, Nashville, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common autoimmune arthritis in children. Polyarticular JIA and extended oligoarticular JIA both have genetic associations near genes…
Abstract Number: 159 • 2020 Pediatric Rheumatology Symposium
Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis
Takako Miyamae¹, Yumi Tani ¹, Manabu Kawamoto ², Takayuki Kishi ³ and Masayoshi Harigai ², ¹Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, TOKYO, Japan, ³Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Long-term outcomes of systemic JIA are highly variable. approximately half of the patients have chronic persistent arthritis requiring extended anti-inflammatory therapy, sometimes into adulthood.…
Abstract Number: 1703 • 2019 ACR/ARP Annual Meeting
Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease
Yue Liu¹, Yan Yang ¹, Rui Su ², Xinyu Zheng ³, Xiao-feng Li ⁴ and Cai-hong Wang ⁵, ¹Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Tai yuan, Shanxi, China (People's Republic), ³Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, Tai Yuan, China (People's Republic), ⁴The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ⁵The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic)
Background/Purpose: Behcet’s disease(BD) is a multisystem inflammatory disorder of unknown etiology.Improved understandings indicate the Th17/Treg immune imbalance may play a critical role in BD's pathogenesis,…
Abstract Number: 1764 • 2019 ACR/ARP Annual Meeting
CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion
Sadiq Umar¹, Katrien Raemdonck ¹, Karol Palasiewicz ¹, Michael Volin ², Shiva Arami ¹, Suncica Volkov ¹, Nadera Sweiss ¹, M Amin ³ and Shiva shahrara ¹, ¹University of Illinois at chicago, Chicago, IL, ²Department of Microbiology & Immunology, Midwestern University, Downer Grove, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Background/Purpose: CCL25 and its receptor CCR9 have been detected in the inflamed joint; however their role is undefined in rheumatoid arthritis (RA). Hence studies…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 2418 • 2019 ACR/ARP Annual Meeting
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
María José Barrera ¹, Sergio Aguilera², Patricia Carvajal ³, Isabel Castro ⁴, Sergio González ⁵, Claudio Molina ¹, Soledad Matus ⁶, Daniela Jara ³ and María Julieta González ³, ¹Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, ²Clínica INDISA, Santiago, Chile, ³ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ⁴Departamento Tecnología Médica, Universidad de Chile, Santiago, Chile, ⁵Escuela de Odontología, Universidad Mayor, Santiago, Chile, ⁶Fundación Ciencia & Vida, Santiago, Chile, Santiago, Chile
Background/Purpose: Sjögren’s syndrome (SS) is an immune-mediated exocrinopathy, where defects in autophagy could contribute to the pathogenesis. Minor labial salivary glands (MLSG) of primary SS…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].